Q-omics provides the consensus-scored MIR4645 profile across patient tissues and cancer cell-line models. MIR4645 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, MIR4645 is differentially expressed in 7, with the highest sampling consensus in KIRC. Additionally, MIR4645 RNA expression shows 14,381 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight UCS, KIRC, and THYM as cancer lineages where MIR4645 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR4645 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR4645 survival associations across molecular data types. MIR4645 RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR4645 RNA expression–survival associations across cancer types. High MIR4645 expression shows unfavorable associations in ACC, LUSC and KIRC, but favorable associations in UCS, HNSC and BLCA. The UCS Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCS as the clearest survival context for MIR4645 RNA expression.
This table summarizes MIR4645 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for MIR4645. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR4645 shows lower tumor expression in LUSC, THCA and BLCA and higher tumor expression in KIRC, CHOL and STAD. The KIRC box plot shows higher MIR4645 RNA expression in tumor versus normal tissue (log2 FC = +1.458, t-test p < 0.001).
This table shows molecular features associated with MIR4645 in patient tissues and cancer cell lines. In patient samples, MIR4645 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
